Benzyl (S)-1-((3-BroMo-4,5-Dihydroisoxazol-5-Yl)MethylaMino)-3-(4-Hydroxyphenyl)-1-Oxopropan-2-YlcarbaMate

KCC009, a transglutaminase 2 (TG2) inhibitor, induces p53-independent radiosensitization[1][2]. The inhibition rates were 15.33±1.46 (%) for H1299/WT-p53 cells, and 14.31±1.90 (%) for H1299/M175H-p53 cells when cells were treated with KCC009 at concentration of 3.91 uM[1].

[1]. Sheng Huaying, et al. Transglutaminase 2 Inhibitor KCC009 Induces p53-Independent Radiosensitization in Lung Adenocarcinoma Cells. Med Sci Monit. 2016 Dec 21;22:5041-5048. [2]. L Yuan, et al. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene